Intra-arterial prourokinase for acute ischemic stroke - The PROACT II study: A randomized controlled trial

Context Intravenous tissue-type plasminogen activator can be beneficial to some patients when given within 3 hours of stroke onset, but many patients present later after stroke onset and alternative treatments are needed. Objective To determine the clinical efficacy and safety of intra-arterial ( IA) recombinant prourokinase (r-proUK) in patients with acute stroke of les s than 6 hours' duration caused by middle cerebral artery (MCA) occlusion. Design PROACT II (Prolyse in Acute Cerebral Thromboembolism II), a randomiz ed, controlled, multicenter, open-label clinical trial with blinded follow- up conducted between February 1996 and August 1998. Setting Fifty-four centers in the United States and Canada. Patients A total of 180 patients with acute ischemic stroke of less than 6 hours' duration caused by angiographically proven occlusion of the MCA and without hemorrhage or major early infarction signs on computed tomographic scan. Intervention Patients were randomized to receive 9 mg of IA r-proUK plus he parin (n = 121)or heparin only (n = 59), Main Outcome Measures The primary outcome, analyzed by intention-to-treat, was based on the proportion of patients with slight or no neurological disa bility at 90 days as defined by a modified Rankin score of 2 or less. Secon dary outcomes included MCA recanalization, the frequency of intracranial he morrhage with neurological deterioration, and mortality. Results For the primary analysis, 40% of r-proUK patients and 25% of contro l patients had a modified Rankin score of 2 or less (P=.04). Mortality was 25% for the r-proUK group and 27% for the control group. The recanalization rate was 66% for the r-proUK group and 18% for the control group (P<.001). Intracranial hemorrhage with neurological deterioration within 24 hours oc curred in 10% of r-proUK patients and 2% of control patients (P=.06). Conclusion Despite an increased frequency of early symptomatic intracranial hemorrhage, treatment with IA r-proUK within 6 hours of the onset of acute ischemic stroke caused by MCA occlusion significantly improved clinical ou tcome at 90 days.